Article info
PDFHealthcare delivery, economics and global health
Original article
Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes
- Correspondence to Dr Iskandar Idris, Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, Royal Derby Hospital, Uttoxeter Road, Derby DE22 3DT, UK; Iskandar.idris{at}nottingham.ac.uk
Citation
Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes
Publication history
- Received December 14, 2015
- Revised April 20, 2016
- Accepted April 29, 2016
- First published May 23, 2016.
Online issue publication
November 13, 2018
Article Versions
- Previous version (13 November 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/